Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
暂无分享,去创建一个
R. Motzer | B. Escudier | S. Oudard | Thomas E. Hutson | Bernard Escudier | Stéphane Oudard | Thomas E Hutson | F. T. 4. Group | Robert J Motzer | for the RECORD-1 Study Group
[1] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[2] Suzanne F. Jones,et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[4] H. Lane,et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Richard Pazdur,et al. End points and United States Food and Drug Administration approval of oncology drugs. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T. Wilt,et al. Targeted therapy for advanced renal cell carcinoma. , 2008, The Cochrane database of systematic reviews.
[7] James Brugarolas,et al. Renal-cell carcinoma--molecular pathways and therapies. , 2007, The New England journal of medicine.
[8] R. Amato,et al. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Bohuslav Melichar,et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.
[10] T. Wilt,et al. Immunotherapy for advanced renal cell cancer. , 2015, The Cochrane database of systematic reviews.
[11] L. Schwartz,et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.
[13] R. Motzer,et al. Renal-cell carcinoma. , 1996, The New England journal of medicine.
[14] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[15] W. Bro,et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[16] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[17] K. K. Lan,et al. Discrete sequential boundaries for clinical trials , 1983 .
[18] William R Sellers,et al. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. , 2003, Cancer cell.
[19] I. Mellinghoff,et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer , 2006, Nature Medicine.
[20] Suzanne F. Jones,et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] W. Kaelin. The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer , 2004, Clinical Cancer Research.
[22] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[23] S. Liou,et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.